Navigation Links
Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting
Date:12/8/2008

y, Philadelphia, PA; SCHWARZ BIOSCIENCES, Inc., (a member of the UCB Group), Research Triangle Park, NC, United States

Evaluation of Lacosamide Efficacy in Subjects with Partial-Onset Seizures Across the Dose Range Used in Phase II/III Clinical Trials

In the individual trials and pooled analysis in this evaluation, Vimpat(R) significantly reduced seizures at all doses studied (200, 400, and 600 mg/day). The individual trials demonstrated that:

-- The 400 and 600 mg/day Vimpat(R) dose groups were significantly different from placebo for both primary efficacy endpoints in all trials using these doses.

-- The 200 mg/day Vimpat(R) dose group demonstrated significant seizure reduction versus placebo in the phase III trial (SP 755), but not in the phase II trial (SP667). To further evaluate the effectiveness of the 200 mg/day dose, a meta-analysis was conducted; results showed a significant difference compared to placebo for both primary endpoints.

The pooled results among patients entering the maintenance period demonstrated statistically significant reductions in seizure frequency at all doses studied compared to placebo:

-- Seizure frequency was significantly reduced by 33.5 percent for the 200 mg/day group (p <.05 ) and by more than 40 percent for the 400 and 600 mg/day groups (41.4 percent and 48.8 percent, respectively), compared with 19.2 percent for placebo (p<.0001).

-- Responder rates (patients with 50 percent or greater reduction in seizure frequency) were 34.8 percent for 200 mg/day (p <.05), 44.3 percent for 400 mg/day, and 48.6 percent for 600 mg/day, and 23.1 percent for placebo (p<.0001).

-- Additionally, there was a dose-responsive trend for improved seizure freedom rates among subjects who completed the maintenance period (2.7 percent, 3.3 percent, and 4.8 percent with increasing Vimpat(R) doses vs. 0.
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium
2. Derma Sciences Announces Multiple Clinical Posters Featuring MEDIHONEY(R) and ALGICELL Ag(R) to be Presented at Upcoming Wound Care Conference
3. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
4. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
5. Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
6. Environmental Tectonics Corporation Announces a Multiple Sale of Hyperbaric Monoplace Chambers to Comprehensive Healthcare Solutions
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting
10. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
11. Environmental Tectonics Corporation Announces a Multiple Sale for Monoplace Hyperbaric Chambers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 The report “Pharmacy ... Systems, Packaging and Labeling Systems, Table-top Counters) by ... Global Forecasts & Trends to 2019” analyzes and ... in North America, Europe, Asia-Pacific, and the Rest ... tables and 30 figures spread through 300 pages ...
(Date:10/20/2014)... , October 20, 2014 ... gastrointestinal (GI) disorders and the delivery of care has ... diseases and worrying inequalities in the provision of healthcare ... which was commissioned by United European Gastroenterology (UEG), have ... political and public awareness of the burden of GI ...
(Date:10/20/2014)... Local veterinary surgeon, Dr. Tim McCarthy is seeking ... stem cells for dogs with osteoarthritis. Dr. McCarthy has ... clinical stem cell therapy for 7 years. The ultimate ... single injection of donor stem cells into one or ... inflammation in the treated joints. , Candidates for ...
(Date:10/19/2014)... 19, 2014 The Asian Automatic patient ... with analysis and forecast of revenue. The Automatic patient ... around $463.9 million by 2018, at a developing CAGR ... the TOC of the Asian Automatic patient billing market, ... This also provides a glimpse of the segmentation of ...
Breaking Biology Technology:Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3
... Wis., Jan. 22 Mach One Corporation,(Pink Sheets: MNCN), ... positive long term benefit to the agricultural and consumer,market, ... Swap of,$1.5 million with an Investor. , ... facilitate the equipment purchase for,its first production facility in ...
... 22 Axikin Pharmaceuticals, Inc., a startup company ... for respiratory and inflammatory diseases, today announced a ... stock. The financing was led by Sanderling ... include Mitsui & Co. Venture Partners of New ...
... Calif., Jan. 22 Abaxis, Inc. (Nasdaq: ABAX ... has scheduled a conference call to discuss its financial results ... 31, 2008. The call will be at 4:15 p.m. ET ... (706) 643-0580 to access the conference call, or can listen ...
Cached Biology Technology:Mach One Completes Note Exchange 2Axikin Pharmaceuticals Spins out of Actimis 2Axikin Pharmaceuticals Spins out of Actimis 3Abaxis to Report Third Quarter Fiscal 2009 Financial Results Thursday, January 29, 2009 2
(Date:10/14/2014)... Cancer Research shows SIRT6—a protein known to ... the development of skin cancers by turning on an ... skin cells. , Previously considered protective, SIRT6 is part ... help regulate genomic stability and prevent some of the ... damage, which can lead to cancer. This study, in ...
(Date:10/14/2014)... to produce enough food to feed the world in ... of the United Nations predicts that food production must ... a growing global population, and plants are one major ... Plants—grains, cereals, fruits, vegetables, and more—feed humans directly and ... into our knowledge of how plants work to develop ...
(Date:10/14/2014)... Scientists from The Scripps Research Institute (TSRI) have been ... (NIH) to lead an investigation of Lassa fever virus, ... The study aims to understand how Lassa fever virus ... survive the inflection. , "The ultimate goal is ... Lassa fever virus causes disease and develop new treatments ...
Breaking Biology News(10 mins):Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3Scripps Research Institute team receives $6.6 million to investigate deadly Lassa virus 2
... of Standards and Technology (NIST), in support of the ... validated the measurement accuracy of new techniques that use ... of cancer. Additional results suggest that a relatively simple ... early detection of some solid tumors, including lung cancer. ...
... the human antibody response to yellow fever, Howard Hughes ... the crucial bit of virus that people's immune systems ... , The findings may help scientists improve the existing ... Jan ter Meulen, an HHMI international research scholar and ...
... establishment of first polarity in the developing mammalian embryo ... biology today. Drs. Davor Solter and Takashi Hiiragi have ... techniques, including comprehensive time-lapse microscopy, the researchers showed compelling ... mouse egg. , Their findings are in contrast to ...
Cached Biology News:Fragment of yellow fever virus may hold key to safer vaccine 2Fragment of yellow fever virus may hold key to safer vaccine 3
1, 2 or 8 PreMixes are included as part of the FailSafe™ PCR System....
1, 2 or 8 PreMixes are included as part of the FailSafe™ PCR System....
Request Info...
... Mung Bean Nuclease catalyzes the degradation ... yield 5-phosphoryl terminated products. While the nuclease ... very high concentrations the enzyme degrades double-stranded ... Nuclease has been used for transcript mapping ...
Biology Products: